Rentschler Biopharma expands U.S. footprin... Prior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s … more ➔
The road to recovery goes via vaccines and...If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful development of vaccines and therapeutic antibodies has the potential to be the beginning of the … more ➔
Product hopping Boon or Bane? Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product … more ➔
Product hopping – Boon or Bane? Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product … more ➔
Expansion through partnershipsImmatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmithKline (GSK) to find novel cancer targets on solid tumours and to direct TCR-T cell therapies against them. European Biotechnology … more ➔
European assets ahead despite virus panicEvery year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 … more ➔
Is your reality quite different from other... While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish … more ➔
Is your reality quite different from other... While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish … more ➔
Determined to grow Spanish 3P Biopharmaceuticals has shown tremendous growth, at least 10 per cent above market growth rate in the past four years. European Biotechnology spoke with Dámaso Molero, CEO of the Spanish … more ➔
Access instead of bureaucracyA newly forming industry association warns the European Commission not to block patients’ access to the emerging EU market for medicinal cannabis. At the BIO-Europe in Hamburg, European Biotechnology … more ➔
